Discovery of a β-arrestin-biased CCKBR agonist that blocks CCKBR-dependent long-term potentiation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41360797.
- Also identified by DOI 10.1038/s41467-025-65962-y and PMC identifier 12686490.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The CCKBR agonists induce neocortical long-term potentiation of excitatory synaptic transmission and enhance memory formation, while its antagonists weaken the potentiation in the amygdala and alleviate depression-like behaviors. However, the mechanism that drives CCKBR dependent long-term potentiation remains elusive. There is also no signaling pathway-biased CCKBR agonist to modulate the potentiation. Here, we discover a β-arrestin biased CCKBR agonist MF-8 with IC<sub>50</sub> = 0.9 nM. The activation of CCKBR with MF-8 fails to induce the potentiation but efficiently induces CCKBR endocytosis. Multi-Electrode Array results demonstrate that the potentiation is dependent on Gα<sub>q/11</sub>-Ca<sup>2+</sup> and Gα<sub>s</sub>-cAMP signaling pathways. The potentiation is entirely blocked by MF-8 through β-arrestin signaling. Furthermore, MF-8 effectively inhibits the formation of cue-to-cue associative fear memory. These results reveal the signal pathway preference of the CCKBR long-term potentiation and identify a blocker of the potentiation, which provides us with broader insights into developing drugs targeting CCKBR.
Medical subject headings
- Long-Term Potentiation
- beta-Arrestins